Peptide Receptor Radionuclide Therapy (PRRT) and impact on quality of life in patients with neuroendocrine neoplasms: An international multi-centre study

#3451

Introduction: Neuroendocrine neoplasms (NENs) affect health-related quality of life (HRQOL) due to tumor burden, hormone-secretory symptoms, and treatment-related side effects.

Aim(s): We assessed the impact of Peptide Receptor Radionuclide Therapy (PRRT) on HRQOL at 4 centres.

Materials and methods: HRQOL data (European Organisation for the Research and Treatment of Cancer QLQ-C30) and clinical data were retrospectively reviewed from patients treated with PRRT between May 2009 -December 2017 (3 sites in Australia, 1 in Canada). Mixed models for repeated measures examined relationships between time (baseline and final PRRT), global health status, functioning (physical, role, emotional, cognitive, social) and symptoms (fatigue, nausea/vomiting, pain, appetite loss, diarrhea).

Conference:

Presenting Author: Kong G

Authors: Kong G, Corsini N, Hogg A, Mercurio J, Bailey D,

Keywords: PRRT, HRQOL, Neuroendocrine neoplasm, Multi-centre study, QLQ-C30,